← Back to Search

Cancer Vaccine

POL-103A for Melanoma (MAVIS Trial)

Phase 3
Waitlist Available
Led By Craig Slingluff, M.D.
Research Sponsored by Polynoma LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 432 events or approximately 10 years
Awards & highlights
Pivotal Trial

Summary

The purpose of this study is to determine how safe and how well POL-103A works in preventing the relapse of melanoma after patients who have undergone surgery.

Eligible Conditions
  • Melanoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~432 events or approximately 10 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 432 events or approximately 10 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Recurrence Free Survival (RFS)
Secondary study objectives
Overall Survival (OS)

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: POL-103AExperimental Treatment1 Intervention
Group II: POL-103A without APIPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Polynoma LLCLead Sponsor
Craig Slingluff, M.D.Principal InvestigatorUniversity of Virginia Hospital
~37 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top